Discover Opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Sep 13, 2024 to Sep 13, 2024
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| National Institutes of Health NIDA | SRI International | Sep 13, 2024 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
PHASE I SINGLE ASCENDING DOSE STUDY. TO7. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 09/10/2024 - 03/09/2026. NIDA REF. NO. N01DA-19-8947.
Effective Date
Sep 9, 2024
Expires
PHASE I SINGLE ASCENDING DOSE STUDY. TO7. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 09/10/2024 - 03/09/2026. NIDA REF. NO. N01DA-19-8947.
ActiveNIDA CENTER FOR GENETIC STUDIES. MARCH 14, 2025 - MARCH 13, 2026. N01DA-23-7787. TASK ORDER 75N95025F00001 (TO3).
Effective Date
Mar 12, 2025
Expires
Effective: Mar 12, 2025
NIDA CENTER FOR GENETIC STUDIES. MARCH 14, 2025 - MARCH 13, 2026. N01DA-23-7787. TASK ORDER 75N95025F00001 (TO3).
ActiveINVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. SEPTEMBER 3, 2024 TO MARCH 2, 2026. N01DA-23-8935
Effective Date
Sep 12, 2024
Expires
INVESTIGATIONAL AGENT SINGLE ASCENDING DOSE SAFETY, TOLERABILITY, AND PK STUDY. SEPTEMBER 3, 2024 TO MARCH 2, 2026. N01DA-23-8935
ActivePHARMACOKINETIC ANALYSIS RESOURCE CENTER. PHASE I SINGLE ASCENDING DOSE STUDY. MAY 15, 2025 - NOVEMBER 14, 2026. N01DA-25-8947. TASK ORDER 75N95025F00001 (TO1).
Effective Date
May 13, 2025
Expires
PHARMACOKINETIC ANALYSIS RESOURCE CENTER. PHASE I SINGLE ASCENDING DOSE STUDY. MAY 15, 2025 - NOVEMBER 14, 2026. N01DA-25-8947. TASK ORDER 75N95025F00001 (TO1).
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis